Lifileucel + pembrolizumab show promise for advanced melanoma in data from phase II study

SITC seeks applications for two fellowships

Applications are now being accepted for the Society for Immunotherapy of Cancer fellowship opportunities. This year, SITC is offering two fellowships totaling $150,000 in funding.

March 20, 2026

Vol.52 No.11

Clinical Roundup

Merck to present long-term data of Gardasil 9 and Gardasil at the EUROGIN international multidisciplinary HPV Congress

Clinical, real-world data reaffirming the long-term effectiveness of Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) and Gardasil (Human Papillomavirus 4-valent Vaccine, Recombinant) against certain HPV-related cancers and diseases will be presented at the EUROGIN International Multidisciplinary HPV Congress 2026 in Vienna, Austria, March 18-21.

March 20, 2026

Vol.52 No.11

Guest Editorial

As more people are surviving cancer, we must continue funding bold science

The cancer research community has a reason to celebrate. For the first time, 70% of people are living at least five years beyond their cancer diagnosis. And, as importantly, cancer death rates have been dropping relentlessly—by more than a third since 1991.

Combination treatment may dramatically improve survival in brain cancer

A study suggests that laser interstitial thermal therapy using NeuroBlate may enhance the effectiveness of the immunotherapy drug pembrolizumab (Keytruda) for patients with recurrent high grade astrocytoma, including glioblastoma.

March 06, 2026

Vol.52 No.09

Drugs & Targets

Keytruda + Padcev reduced risk of EFS and death for muscle-invasive bladder cancer when given before and after surgery

Keytruda (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) reduced the risk of event-free survival events by 47% and reduced the risk of death by 35% when given before and after surgery versus neoadjuvant chemotherapy and surgery in patients with muscle-invasive bladder cancer who are eligible for cisplatin-based chemotherapy.

March 06, 2026

Vol.52 No.09

Clinical Roundup

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

Data from the phase Ib/II OrigAMI-4 study found that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination with a PD-1 inhibitor delivered clinically meaningful and durable antitumor activity in patients with head and neck squamous cell carcinoma that is recurrent or metastatic, PD-L1-positive, and HPV-unrelated.

February 27, 2026

Vol.52 No.08

Lifileucel + pembrolizumab show promise for advanced melanoma in data from phase II study

YOU MAY BE INTERESTED IN

SITC seeks applications for two fellowships

Merck to present long-term data of Gardasil 9 and Gardasil at the EUROGIN international multidisciplinary HPV Congress

As more people are surviving cancer, we must continue funding bold science

Combination treatment may dramatically improve survival in brain cancer

Keytruda + Padcev reduced risk of EFS and death for muscle-invasive bladder cancer when given before and after surgery

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

Renew today!

Subscriber content

Never miss an issue!

Login